David Stirling

12.3k citations

109 papers · 10.1k indexed · 6 hit papers · h-index 47

Impact in

Hematology top 0.1%
- Multiple Myeloma Research and Treatments
Genetics top 0.5%
- Chronic Lymphocytic Leukemia Research

Papers in

Hematology 61
- Multiple Myeloma Research and Treatments 60
Genetics 10
- Chronic Lymphocytic Leukemia Research 9

Co-authors: George W. Muller Howard Dalton Laura G. Corral Gilla Kaplan Peter Schäfer Roger Chen John Colby Angus Dalgleish
Journals: Blood (13 papers)Bioorganic & Medicinal Chemistry Letters (3 papers)The Journal of Immunology (3 papers)Cancer Research (3 papers)Seminars in Oncology (3 papers)
Partner nations: United Kingdom United States Switzerland

In The Last Decade

David Stirling

109 papers receiving 9.8k citations

Hit Papers

6 papers align trajectories log scale

Gold Nanoparticles for the Improved Anticancer Drug Delivery of the Active Component of Oxaliplatin 2010 · 678 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2010 Journal of the American Chemical Society
2001 Blood
2000 Blood
1999 PubMed
1999 The Journal of Immunology
1977 Biochemical Journal

Peers

Countries citing papers authored by David Stirling

Since Specialization

Citations

This map shows the geographic impact of David Stirling's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Stirling with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Stirling more than expected).

Fields of papers citing papers by David Stirling

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Stirling. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Stirling. The network helps show where David Stirling may publish in the future.

Co-authors

The 25 scholars most cited alongside David Stirling, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with David Stirling Line = papers co-authored together David Stirling links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Measurement of arsenic and gallium content of gallium arsenide semiconductor waste streams by ICP-MS Journal of Environmental Science and Health Part A ·Henry Siy, Helen Keenan, Andrew Hursthouse, David Stirling	2010	21
2	The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells Cancer Immunology Immunotherapy ·Christine Galustian, B Meyer, Marie‐Christine Labarthe, Keith Dredge, О.В. Гагарина, Jake Y. Henry, Stephen Todryk, Roger Chen, George W. Muller, David Stirling, Peter Schäfer, J. Blake Bartlett, Angus Dalgleish	2008	324
3	The anticancer drug lenalidomide inhibits angiogenesis and metastasis via multiple inhibitory effects on endothelial cell function in normoxic and hypoxic conditions Molecular Cancer Therapeutics ·J. Blake Bartlett, Ling Lu, Faribourz Payvandi, Lei Wu, Linghua Zhang, George W. Muller, David Stirling, Peter Schäfer	2007	2
4	Lenalidomide inhibits proliferation of Namalwa CSN.70 cells and interferes with Gab1 phosphorylation and adaptor protein complex assembly Leukemia Research ·Anita K. Gandhi, Jian Kang, A Ascione, Anastasia Parton, Peter Schäfer, David Stirling	2006	73
5	Immunomodulatory Drugs (IMiDs) Increase the Production of IL-2 from Stimulated T Cells by Increasing PKC-θ Activation and Enhancing the DNA-Binding Activity of AP-1 but Not NF-κB, OCT-1, or NF-AT Journal of Interferon & Cytokine Research ·Faribourz Payvandi, Lei Wu, A Ascione, Xavier Bell�s, Anastasia Parton, Peter Schäfer, Roger S. Chen, George W. Muller, Christopher C.W. Hughes, David Stirling	2005	40
6	Orally administered lenalidomide (CC-5013) is anti-angiogenic in vivo and inhibits endothelial cell migration and Akt phosphorylation in vitro Microvascular Research ·Keith Dredge, Henry Fuller Howden, Simon P. Robinson, Linghua Zhang, Ling Lu, Yang Tang, Michael A. Shirley, George W. Muller, Peter Schäfer, David Stirling, Angus Dalgleish, J. Blake Bartlett	2005	225
7	A novel PDE4 inhibitory agent with endothelial cell specific activity. Cancer Research ·Jennifer E. Rosen, 珠材酒井, Mei He, Wu Xing an, H. Richard Alexander, Faribourz Payvandi, David Stirling, Peter Schäfer, Steven K. Libutti	2004	1
8	A novel technique for quantifying changes in vascular density, endothelial cell proliferation and protein expression in response to modulators of angiogenesis using the chick chorioallantoic membrane (CAM) assay Journal of Translational Medicine ·珠材酒井, Mark L. Kayton, Sņežana Lukša, Wu Xing an, Mei He, JEREMY FREESE, Galina Baibakov, Dominique Lorang, Vladimir Knežević, Elise C. Kohn, H. Richard Alexander, David Stirling, Faribourz Payvandi, George W. Muller, Steven K. Libutti	2004	29
9	Remodelling of the PDE4 cAMP phosphodiesterase isoform profile upon monocyte‐macrophage differentiation of human U937 cells British Journal of Pharmacology ·Malcolm Shepherd, George S. Baillie, David Stirling, Miles D. Houslay	2004	82
10	A novel subclass of thalidomide analogue with anti-solid tumor activity in which caspase-dependent apoptosis is associated with altered expression of bcl-2 family proteins. PubMed ·J B Marriott, Ian Clarke, Anna Czajka, Keith Dredge, Kay Childs, Hon‐Wah Man, Peter Schäfer, T. L. Rokoske, George W. Muller, David Stirling, Angus Dalgleish	2003	45
11	Neurobehavioral effects of racemic threo-methylphenidate and its d and l enantiomers in rats Pharmacology Biochemistry and Behavior ·Steve K. Teo, David Stirling, Steve D. Thomas, Vikram Khetani	2003	28
12	Chiral inversion of the second generation IMiD™ CC‐4047 (ACTIMID™) in human plasma and phosphate‐buffered saline Chirality ·Steve K. Teo, Yong Chen, George W. Muller, Roger S. Chen, Steve D. Thomas, David Stirling, Jaime Ramón Holguín-Peña	2003	23
13	α-Fluoro-substituted thalidomide analogues Bioorganic & Medicinal Chemistry Letters ·Hon‐Wah Man, Laura G. Corral, David Stirling, George W. Muller	2003	38
14	Immunomodulatory analogs of thalidomide inhibit growth of Hs Sultan cells and angiogenesis in vivo Leukemia ·Suzanne Lentzsch, Richard LeBlanc, Klaus Podar, Faith E. Davies, Boris K. Lin, Teru Hideshima, Laurence Catley, David Stirling, Kenneth C. Anderson	2003	130
15	Protective Antitumor Immunity Induced by a Costimulatory Thalidomide Analog in Conjunction with Whole Tumor Cell Vaccination Is Mediated by Increased Th1-Type Immunity The Journal of Immunology ·Keith Dredge, J B Marriott, Stephen Todryk, George W. Muller, Roger Chen, David Stirling, Angus Dalgleish	2002	143
16	A 90-day oral gavage toxicity study of d-methylphenidate and d,l-methylphenidate in Sprague–Dawley rats Toxicology ·Steve Teo, David Stirling, Steve D. Thomas, Alan M. Hoberman, Anthony L. Kiorpes, Vikram Khetani	2002	297
17	Thalidomide for the Treatment of AIDS-Associated Wasting AIDS Research and Human Retroviruses ·Gilla Kaplan, Steve D. Thomas, Daniel S. Fierer, Kathleen Mulligan, Patrick Haslett, W. Jeffrey Fessel, Leon G. Smith, Karin A. Kook, David Stirling, Morris Schambelan	2000	67
18	Co-metabolism Philosophical transactions of the Royal Society of London. Series B, Biological sciences ·Howard Dalton, David Stirling	1982	167
19	The fortuitous oxidation and cometabolism of various carbon compounds by whole-cell suspensions ofMethylococcus capsulatus(Bath) FEMS Microbiology Letters ·David Stirling, Howard Dalton	1979	98
20	The fortuitous oxidation and cometabolism of various carbon compounds by whole-cell suspensions of Methylococcus capsulatus (Bath) FEMS Microbiology Letters ·David Stirling	1979	1

About David Stirling

David Stirling is a scholar working on Hematology, Genetics, Molecular Biology, Cancer Research and Oncology, having authored 109 papers that have together received 10.1k indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (60 papers), Protein Degradation and Inhibitors (25 papers), Chronic Lymphocytic Leukemia Research (9 papers), Microbial metabolism and enzyme function (8 papers), Cancer Treatment and Pharmacology (8 papers), Attention Deficit Hyperactivity Disorder (7 papers), Phosphodiesterase function and regulation (7 papers) and Cancer therapeutics and mechanisms (6 papers). The work is most often cited by research in Hematology (4.8k citations), Genetics (1.2k citations), Oncology (2.7k citations), Molecular Biology (5.3k citations) and Immunology (1.4k citations). David Stirling has collaborated with scholars based in United Kingdom, United States and Switzerland. Frequent co-authors include George W. Muller, Howard Dalton, Laura G. Corral, Gilla Kaplan, Peter Schäfer, Roger Chen, John Colby, Angus Dalgleish, Patrick Haslett and Christopher Ocampo. Their work appears in journals such as Blood, Bioorganic & Medicinal Chemistry Letters, The Journal of Immunology, Cancer Research and Seminars in Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact